Basic Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Nov 15, 2023; 14(11): 1659-1671
Published online Nov 15, 2023. doi: 10.4239/wjd.v14.i11.1659
Molecular targets and mechanisms of Jiawei Jiaotai Pill on diabetic cardiomyopathy based on network pharmacology
Yu-Juan Wang, Yan-Li Wang, Xiao-Fan Jiang, Juan-E Li
Yu-Juan Wang, Department of Otolaryngology, Shaanxi Provincial People’s Hospital, Xi’an 710068, Shaaxi Province, China
Yan-Li Wang, Department of Pediatrics, Affiliated Hospital of Traditional Chinese Medicine, Xinjiang Medical University, Urumqi 830000, Xinjiang Uygur Autonomous Region, China
Xiao-Fan Jiang, Juan-E Li, Department of Chinese Medicine, Shaanxi Provincial People’s Hospital, Xi’an 710068, Shaaxi Province, China
Author contributions: Wang YJ and Wang YL contributed to the literature search; Jiang XF performed the data acquisition and statistical analysis; Li JE contributed to the manuscript preparation and editing; All authors have approved the final manual.
Supported by Natural Science Basic Research Plan in the Shaanxi Province of China, No. 2021JM-549, The Plan Project of Shaanxi Provincial Administration of Traditional Chinese Medicine, No. 2021-ZZ-JC011; and The Second Youth Science and Technology Talents Project of Shaanxi Provincial Administration of Traditional Chinese Medicine, No. 2023-ZQNY-017.
Institutional review board statement: The data used in this study are all public data from public databases, and do not involve human or animals data, so there is no need for ethical review.
Conflict-of-interest statement: The authors declare no conflict of interest.
Data sharing statement: The data used for this study can be obtained from the corresponding authors at lizhuan-1980@126.com.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Juan-E Li, MD, Associate Chief Physician, Department of Chinese Medicine, Shaanxi Provincial People’s Hospital, No. 256 Youyi West Road, Beilin District, Xi’an 710068, Shaaxi Province, China. lizhuan-1980@126.com
Received: June 20, 2023
Peer-review started: June 20, 2023
First decision: July 7, 2023
Revised: July 12, 2023
Accepted: October 8, 2023
Article in press: October 8, 2023
Published online: November 15, 2023
Processing time: 146 Days and 22.7 Hours
ARTICLE HIGHLIGHTS
Research background

Diabetic cardiomyopathy (DCM) is a type of cardiomyopathy independent of hypertension, coronary artery disease, and vascular complications. Traditional Chinese medicine (TCM) has unique advantages for treating this disease. In the current study, Jiawei Jiaotai Pill was widely used for the treatment of diabetes and its complications. Jiawei Jiaotai Pill has increased the use of Radix Astragali and Puerariae Lobatae Radix. It was also found that these two drugs had protective effects on the heart.

Research motivation

To improve the efficacy in DCM patients and further clarify the pharmacological basis of the Jiawei Jiaotai Pill, it is necessary to study the molecular mechanism of the Jiawei Jiaotai Pill in the treatment of DCM.

Research objectives

Based on the network pharmacology method and molecular docking technology, this study analyzed the effective active ingredients and important gene targets in Jiawei Jiaotai Pill and provided a reference for clinical treatment.

Research methods

The targets of the four TCMs in Jiawei Jiaotai Pill for DCM were identified using relevant databases. The core targets and compounds were identified using a protein-protein interaction network and a drug-active ingredient-target network. Gene ontology and Kyoto Encyclopedia of Genes and Genomes analyses were used to determine the related pathways of biological processes, and molecular docking was performed for verification.

Research results

The main components of Jiawei Jiaotai Pill used in the treatment of DCM are quercetin, formononetin, kaempferol, 7-O-methylisomucronulatol, and isorhamnetin. These components can act synergistically on disease-related target proteins such as tumor necrosis factor, interleukin-6 (IL-6), cellular tumor antigen p53, epidermal growth factor receptor, and insulin, and play therapeutic roles through the AGE-RAGE signaling pathway, PI3K/Akt, IL-17, and mitogen-activated protein kinase pathways. However, as predicted, the specific mechanism of Jiawei Jiaotai Pill requires further verification.

Research conclusions

The active ingredients of Jiawei Jiaotai Pill have a complex mechanism involving multiple components, targets, and pathways in the treatment of DCM, which may protect myocardial function by reducing the level of oxidative stress, reducing cardiomyocyte apoptosis and fibrosis, and maintaining metabolic homeostasis.

Research perspectives

Based on network pharmacology and molecular docking technology, the related mechanism of Jiawei Jiaotai Pill in the treatment of DCM was speculated, providing a reference for future experimental verification.